FGL2 抗体
(Fibrinogen-Like 2 (FGL2))
The protein encoded by this gene is a secreted protein that is similar to the beta- and gamma-chains of fibrinogen. The carboxyl-terminus of the encoded protein consists of the fibrinogen-related domains (FRED). The encoded protein forms a tetrameric complex which is stabilized by interchain disulfide bonds. This protein may play a role in physiologic functions at mucosal sites. [provided by RefSeq, Jul 2008].
| Catalog no. | 产品 | 适用 | 宿主 / 克隆类型 | 应用 | 价格和交货时间 |
|---|---|---|---|---|---|
| FGL2 抗体 (AA 24-123) | 人 | 小鼠 Monoclonal |
|
|
|
| FGL2 抗体 (C-Term) | 人 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 24-123) | 人 | 小鼠 Monoclonal |
|
|
|
| FGL2 抗体 (AA 1-439) | 人 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 75-150) | 大鼠 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (C-Term) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 20-432) | 小鼠 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 24-439) | 人 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 251-300) | 人, 小鼠, 大鼠, 犬, 马, Pig, Bat, 猴 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 24-140) | 人 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (N-Term) | 人 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 1-439) | 人 | 小鼠 Polyclonal |
|
|
|
| FGL2 抗体 (AA 24-439) | 人 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 20-432) | 小鼠 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (Middle Region) | 人, 小鼠, 大鼠, 犬, 马, Pig, Cow, 豚鼠, 兔 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 75-150) (AbBy Fluor® 594) | 大鼠 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 75-150) (AbBy Fluor® 680) | 大鼠 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 75-150) (AbBy Fluor® 350) | 大鼠 | 兔 Polyclonal |
|
|
|
| FGL2 抗体 (AA 75-150) (AbBy Fluor® 488) | 大鼠 | 兔 Polyclonal |
|
|
Primary Antibody
- WB (Western Blotting: 有验证图片)
- ELISA (ELISA: 有验证图片)
- IP (Immunoprecipitation: 有验证图片)
- ISt (Immunostaining: 有验证图片)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 所列应用)
11 references - 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- 6D9
- 标记
- unconjugated
- 抗体亚型
- IgG2a
- 抗原表位
- AA 24-123
Primary Antibody
- WB (Western Blotting: 有验证图片)
- FACS (Flow Cytometry: 有验证图片)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 克隆
- RB19509
- 标记
- unconjugated
- 抗体亚型
- Ig Fraction
- 抗原表位
- AA 338-367, C-Term
Primary Antibody
- WB (Western Blotting: 有验证图片)
- ELISA (ELISA: 有验证图片)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- 5A10
- 标记
- unconjugated
- 抗体亚型
- IgG1
- 抗原表位
- AA 24-123
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IP (Immunoprecipitation: 有验证图片)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- AA 1-439
Primary Antibody
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 有验证图片)
- IHC (Immunohistochemistry: 有验证图片)
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- IHC (fro) (Immunohistochemistry (Frozen Sections): 所列应用)
- 适用
- 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 75-150
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 有验证图片)
- IHC (Immunohistochemistry: 所列应用)
- ELISA (ELISA: 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 有验证图片)
- IHC (Immunohistochemistry: 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- C-Term
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (Immunohistochemistry: 有验证图片)
- 适用
- 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 20-432
Primary Antibody
- IHC (Immunohistochemistry: 有验证图片)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 24-439
Primary Antibody
- WB (Western Blotting: 有验证图片)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 24-140
Primary Antibody
- WB (Western Blotting: 有验证图片)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- N-Term
Primary Antibody
- WB (Western Blotting: 有验证图片)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- AA 1-439
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (Immunohistochemistry: 有验证图片)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 24-439
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 有验证图片)
- IHC (Immunohistochemistry: 所列应用)
- IP (Immunoprecipitation: 所列应用)
- IF/ICC (Immunofluorescence (fixed cells): 所列应用)
- 适用
- 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- AA 20-432
Primary Antibody
- WB (Western Blotting: 有验证图片)
- 适用
- 人, 小鼠, 大鼠, 犬, 马, Pig, Cow, 豚鼠, 兔
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- Middle Region
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 594
- 抗体亚型
- IgG
- 抗原表位
- AA 75-150
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 680
- 抗体亚型
- IgG
- 抗原表位
- AA 75-150
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 350
- 抗体亚型
- IgG
- 抗原表位
- AA 75-150
Primary Antibody
- WB (Western Blotting: 所列应用)
- FACS (Flow Cytometry: 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- 适用
- 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 488
- 抗体亚型
- IgG
- 抗原表位
- AA 75-150
Latest Publications for our FGL2 抗体
: "Complement factor 5 blockade reduces porcine myocardial infarction size and improves immediate cardiac function." in: Basic research in cardiology, Vol. 112, Issue 3, pp. 20, (2017) (PubMed).
: "Transgenic Expression of Human Thrombomodulin Inhibits HMGB1-Induced Porcine Aortic Endothelial Cell Activation." in: Transplantation, Vol. 100, Issue 9, pp. 1871-9, (2016) (PubMed).
: "Sodium tanshinone IIA sulfonate ameliorates experimental coronary no-reflow phenomenon through down-regulation of FGL2." in: Life sciences, Vol. 142, pp. 8-18, (2015) (PubMed).
: "Immune tolerance. Regulatory T cells generated early in life play a distinct role in maintaining self-tolerance." in: Science (New York, N.Y.), Vol. 348, Issue 6234, pp. 589-94, (2015) (PubMed).
: "Intestinal and peripheral fibrinogen-like protein 2 expression in inflammatory bowel disease." in: Digestive diseases and sciences, Vol. 59, Issue 4, pp. 769-77, (2014) (PubMed).
: "Novel antibody against a glutamic acid-rich human fibrinogen-like protein 2-derived peptide near Ser91 inhibits hfgl2 prothrombinase activity." in: PLoS ONE, Vol. 9, Issue 4, pp. e94551, (2014) (PubMed).
: "Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma." in: Hepatology international, Vol. 8, Issue 4, pp. 567-575, (2014) (PubMed).
: "C5a/C5aR pathway is essential for the pathogenesis of murine viral fulminant hepatitis by way of potentiating Fgl2/fibroleukin expression." in: Hepatology (Baltimore, Md.), Vol. 60, Issue 1, pp. 114-24, (2014) (PubMed).
: "Combined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice." in: PLoS ONE, Vol. 8, Issue 11, pp. e82330, (2013) (PubMed).
: "Correlation of fibrinogen-like protein 2 with disease progression in patients with severe acute pancreatitis." in: Experimental and therapeutic medicine, Vol. 7, Issue 1, pp. 85-89, (2013) (PubMed).
: "Transgenic Expression of Human Thrombomodulin Inhibits HMGB1-Induced Porcine Aortic Endothelial Cell Activation." in: Transplantation, Vol. 100, Issue 9, pp. 1871-9, (2016) (PubMed).
: "Sodium tanshinone IIA sulfonate ameliorates experimental coronary no-reflow phenomenon through down-regulation of FGL2." in: Life sciences, Vol. 142, pp. 8-18, (2015) (PubMed).
: "Immune tolerance. Regulatory T cells generated early in life play a distinct role in maintaining self-tolerance." in: Science (New York, N.Y.), Vol. 348, Issue 6234, pp. 589-94, (2015) (PubMed).
: "Intestinal and peripheral fibrinogen-like protein 2 expression in inflammatory bowel disease." in: Digestive diseases and sciences, Vol. 59, Issue 4, pp. 769-77, (2014) (PubMed).
: "Novel antibody against a glutamic acid-rich human fibrinogen-like protein 2-derived peptide near Ser91 inhibits hfgl2 prothrombinase activity." in: PLoS ONE, Vol. 9, Issue 4, pp. e94551, (2014) (PubMed).
: "Soluble FGL2, a novel effector molecule of activated hepatic stellate cells, regulates T-cell function in cirrhotic patients with hepatocellular carcinoma." in: Hepatology international, Vol. 8, Issue 4, pp. 567-575, (2014) (PubMed).
: "C5a/C5aR pathway is essential for the pathogenesis of murine viral fulminant hepatitis by way of potentiating Fgl2/fibroleukin expression." in: Hepatology (Baltimore, Md.), Vol. 60, Issue 1, pp. 114-24, (2014) (PubMed).
: "Combined adenovirus-mediated artificial microRNAs targeting mfgl2, mFas, and mTNFR1 protect against fulminant hepatic failure in mice." in: PLoS ONE, Vol. 8, Issue 11, pp. e82330, (2013) (PubMed).
: "Correlation of fibrinogen-like protein 2 with disease progression in patients with severe acute pancreatitis." in: Experimental and therapeutic medicine, Vol. 7, Issue 1, pp. 85-89, (2013) (PubMed).
Aliases for FGL2 抗体
fibrinogen like 2 (FGL2) 抗体fibrinogen like 2 L homeolog (fgl2.L) 抗体
fibrinogen-like 2a (fgl2a) 抗体
fibrinogen-like 2 (Fgl2) 抗体
fibrinogen-like protein 2 (Fgl2) 抗体
AI385601 抗体
FGL2 抗体
fibroleukin 抗体
musfiblp 抗体
pT49 抗体
si:ch211-276e22.3 抗体
T49 抗体
wu:fj83c10 抗体
zgc:136619 抗体
您还需要查找其他产品吗？
You are here:
